Cancer drug shows promise in taming rare blood disorder

This study tests whether the drug imatinib (Gleevec) can safely lower high levels of eosinophils (a type of white blood cell) in people with a rare condition called hypereosinophilic syndrome. About 70 participants with the myeloid form or those who didn't respond to steroids will take imatinib daily, with doses adjusted based on response. The goal is to bring eosinophil counts to normal and reduce organ damage, while allowing some patients to eventually stop the drug.